Financial News Archive

SEC EDGAR · Federal Reserve · FDA · BLS · Updated every 60s

Bally's
Bally's amends credit agreement

Bally's Corp entered into a Fifth Amendment to its Credit Agreement, effective July 29, 2026, with existing lenders including Deutsche Bank AG New Yor...

NEWS
News Corp updates buy-back program to aggregate $1B

News Corp has updated its repurchase program to allow for the purchase of up to an aggregate of US$1 billion of its securities. The buy-back involves ...

GRIFFON
Griffon Q3 Revenue Up 7%; Shares Return Positive

Griffon reported third quarter revenue growth of 7% to $481.4 million and adjusted EPS of $1.51, driven by favorable price and mix. The positive earni...

Stardust
Stardust Power Signs Letter of Intent with Charge CCCV for Lithium Supply

Stardust Power entered a non-binding offtake agreement with Charge CCCV LLC for battery-grade lithium carbonate, with projected demand of 3,000 MT in ...

GIBRALTAR
Gibraltar报告Q2营收增65% 调后EPS$1.11

Gibraltar Industries凭借OmniMax收购及有机增长,第二季度营收大涨65%,OmniMax整合加速且大客户获更多订单。...

Holley
Holley Reports Q2 2026 Results with Net Sales Growth, Core Growth, and Portfolio Rebalancing

Holley's net sales grew 3.2% to $172.0M for Q2 2026, driven by a 4.9% increase in core business sales. The company reported a net loss of $(2.4M), par...

Immuneering
Immuneering Reports Q2 2026 Financial Results and Key Updates

Immuneering Corp (IMRX) reported its Q2 2026 financials. The company announced positive interim Phase 2a pancreatic cancer data and is dosing patients...

EVgo
EVgo reports Q2 charging revenue up 19%

EVgo delivered Q2 2026 revenue and network growth, highlighted by a new agreement with Tesla to deploy Superchargers....

Bioventus
Bioventus Q2 revenue increases 4% to $153.2M

Bioventus reported Q2 financial results with revenue and GAAP earnings rising. The company initiated a review of strategic alternatives at a positive ...

Medline
Medline Q2 sales rise 11.6% on strong growth, net income falls 58.3%

Medline reported Q2 2026 net sales of $7.7 billion, up 11.6%, while net income dropped 58.3% primarily due to a $336 million fire loss. The company ra...

Royalty
Royalty Pharma Rises Portfolio Receipts Guidance to $3.4-$3.5B

The company reported strong Q2 2026 results and raised its full-year Portfolio Receipts guidance range. Additionally, it announced capital deployment ...

Summit
Summit Launches Globally Study of Ivonescimab in Bladder Cancer

Summit Therapeutics announced the HARMONi-GU1 Phase II/III trial for ivonescimab in first-line bladder cancer. The study targets a major indication fo...

VISHAY
Vishay Q2 2026 Revenues Exceed Guidance

Vishay reported GAAP revenues of $888.6 million and adjusted revenues of $918.6 million for Q2 2026, exceeding guidance amidst a strengthening upcycle...

ContextLogic
ContextLogic enters stock purchase agreement for acquisition by EagleTree

ContextLogic entered a stock purchase agreement dated Aug. 4, 2026, to be acquired by an EagleTree entity in an all-stock transaction, subject to regu...

Kyndryl
Kyndryl reports first quarter fiscal 2027 results with net loss of $55 million

Kyndryl reported a net loss of $55 million for the first quarter of fiscal 2027, excluding a $152 million workforce rebalancing charge. The company re...

Prologis,
Prologis, Inc. offering 15M shares via JPMorgan, BofA

Prologis, Inc. is selling 15,000,000 shares of common stock through underwriters J.P. Morgan Securities LLC and BofA Securities, Inc. The deal referen...

CDW
CDW appoints CFO as executive advisor

CDW Corp agreed to retain former CFO Albert J. Miralles as an executive advisor to support growth initiatives through March 2028....

CS
DISCO posts Q2 2026 up 13% with $43.1M in revenue

CS Disco reported second quarter 2026 total revenue of $43.1 million, a 13% year-over-year increase. The company also issued full-year 2026 revenue an...

LIFECORE
Lifecore reports Q2 2026 results amid mixed revenue and profit figures inside guidance

Lifecore reported $34.2 million in Q2 2026 revenues, a decrease of 6.2%, with gross margins declining and a wider net loss. Despite current financial ...

Rapport
Rapport Reports Q2 2026 Financials and Initiates RAP-219 Phase 3 Trials

Rapport Therapeutics reported Q2 2026 financials and announced the initiation of FOCUS 1 and 2 Phase 3 trials for RAP-219. The company maintains stron...